Congenital amegakaryocytic thrombocytopenia

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited bone marrow failure disorder characterized by severe thrombocytopenia (very low platelet counts) present from birth, caused by a marked reduction or absence of megakaryocytes — the bone marrow cells responsible for producing platelets. The condition is primarily caused by mutations in the MPL gene, which encodes the thrombopoietin receptor (c-Mpl), essential for megakaryocyte development and platelet production. Without a functional thrombopoietin receptor, the bone marrow cannot adequately produce platelets, leading to dangerous bleeding complications. Infants with CAMT typically present in the neonatal period with severe thrombocytopenia, often manifesting as petechiae (small red or purple spots on the skin), bruising, and potentially life-threatening bleeding episodes including intracranial hemorrhage. The bone marrow initially shows isolated absence or severe reduction of megakaryocytes, but over time, CAMT frequently progresses to pancytopenia and aplastic anemia (failure of all blood cell lineages), usually within the first few years of life. Two clinical subtypes have been described: Type I (complete loss of MPL function) presents with more severe thrombocytopenia and earlier progression to bone marrow failure, while Type II (partial MPL function) may show a transient improvement in platelet counts before eventual marrow failure. The only curative treatment for CAMT is allogeneic hematopoietic stem cell transplantation (bone marrow transplant), which should be considered early in the disease course before the development of complete bone marrow failure. Supportive care includes platelet transfusions to manage or prevent bleeding episodes, though repeated transfusions carry risks of alloimmunization. Standard thrombopoietin receptor agonists are generally ineffective because the underlying defect involves the receptor itself. Without transplantation, the prognosis is poor, with most patients developing severe aplastic anemia in early childhood.

Common questions about Congenital amegakaryocytic thrombocytopenia